1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F7AB9E2013805EA765258384001AFB68
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-competitive-intelligence-landscape-assessment-business-models-structures-policies?opendocument
18
19opendocument
20100.26.182.28
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Competitive and Business Intelligence Structure and Alignment

Competitive Intelligence Landscape Assessment: Business Models, Structures and Policies

ID: 5542


Features:

18 Info Graphics

4 Data Graphics

36 Metrics

4 Narratives


Pages/Slides: 30


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Competitive Intelligence Landscape Assessment: Business Models, Structures and Policies”

STUDY OVERVIEW

In the constantly evolving and complex biopharma marketplace, the Competitive Intelligence function plays an important role in corporate success by helping organizations anticipate and deploy strategic responses to external threats and opportunities. The structure and policies of a Competitive Intelligence group have a significant impact on its effectiveness.

Best Practices, LLC conducted this landscape assessment using a meta-analysis approach to identify evolutionary insights for Competitive Intelligence business models, structures, policies and use of Centers of Excellence in the biopharmaceutical industry. Insights in this research have been distilled from 10 of Best Practices, LLC’s existing benchmarking studies.

KEY TOPICS

  • Consensus definition of competitive intelligence
  • Competitive intelligence business models
  • Structure analysis
  • Using centers of excellence (CoE) to balance efficiency & expertise
  • Global structures and policies leading local functions

KEY METRICS
  • Which of the listed statements most closely describes the structure/ operating model for your Competitive Intelligence function?
  • General FTE range within different Competitive Intelligence group structures
  • How is your company’s Commercial / Marketing function organized?

SAMPLE KEY FINDINGS
  • Competitive Intelligence Structural Forms: As companies grow larger, Competitive Intelligence often moves closer to internal stakeholders, pulling them into decentralized & hybrid forms.
  • Competitive Intelligence Cornerstones: Competitive Intelligence models are built on four cornerstones, evolving from self-service towards more consultative approaches where experienced Competitive Intelligence staff increasingly provide future-focused analysis to inform senior leadership decision-making - Service Level, Staffing, Information Types, and Analytic Perspective.

METHODOLOGY

Best Practices, LLC captured data from ten of its benchmarking studies to conduct a Competitive Intelligence Landscape Assessment for the biopharmaceutical sector.


Industries Profiled:
Medical Device; Pharmaceutical; Health Care; Diagnostic; Manufacturing; Biotech; Biopharmaceutical; Technology; Communications; Consumer Products; Banking; Financial Services; Insurance; Research; Marketing; Chemical; High Tech; Consulting; Service; Electronics; Internet; Distribution; Computer Software; Energy; Clinical Research; Laboratories; Computers; Utilities; Telecommunications; Engineering; Shipping; Professional Services; Logistics; Science


Companies Profiled:
3M Pharmaceuticals; Abbott; Abbott Nutrition; Abbott Laboratories; AbbVie; actavis; Aditya Birla Group; Adocia; Alcon; Alcon Laboratories; Alembic; Alkermes; Allergan; Alnylam Pharmaceuticals; Amgen; Amylin; Anoto; ApotheCom; ARIAD; Array BioPharma; Astellas; AstraZeneca; B.Braun; Bausch & Lomb; Baxter Healthcare; Baxter International; Bayer Healthcare; Bayer; Biocon; BioCryst Pharmaceuticals; Biogen; Biogen Idec; Biological E. Limited; BioMarin; Biovail; Bioventus; Boehringer Ingelheim; Bristol-Myers Squibb; Cadila Pharmaceuticals; Centocor; Inc.; Central Bank of India; Citibank; Colorcon; ConjuChem Biotechnologies; Covance; Covidien; CSL Behring; Cubist Pharmaceuticals; Daiichi Sankyo; Datamatics Financial Services; Dendreon Corporation; Dentsply International; Diners Club International; doTerra; Dr Reddy's Laboratories; Eisai; Eli Lilly and Company; EMD Serono; Emergent BioSolutions; Endo Pharmaceuticals; Essilor International S.A.; Ethicon Endo-Surgery Inc.; Ethicon; Johnson & Johnson; Ethos Health Communications; Farma Health; Ferring Pharmaceuticals; Genentech; GlaxoSmithKline ; Gilead Sciences; Glenmark; Grifols; Human Genome Sciences; IBM; Immunex; IMS Health; Indegene Lifesystems; Infosys; Inspire Pharmaceuticals; Intel; Intermountain Healthcare; Ipsen; Ironwood; Janssen; Jazz Pharmaceuticals; King Pharmaceuticals; Kodak; Lac Mac; Lilly; Lonza Inc.; Mallinckrodt; McKesson; MedImmune; Medtronic; Medrad; Merck; Merck Serono; MyDataBall; Novartis; Nova Nordisk; Oracle; Orion Pharmaceuticals; PDL; PDL BioPharma; Pfizer; Pharma Consulting; Phillips; Procter & Gamble Pharma; Progress Energy; ProStrakan; Purdue Pharma; Quintiles; Ranbaxy; Roche; Rxperts; Salt Creek Biosciences; Sanofi; Sanofi Pasteur; Sanofi-Aventis; Santen; SAS; Sequor; Shire; Stiefel; Sunovion; Syntel; Takeda Pharmaceuticals; Tata Technologies; Teleflex; Tesaro; Teva Pharmaceutical Industries Ltd; Theratechnologies; Torrent Pharmaceuticals Ltd.; Transform Strategy Partners; UCB Pharma; UPS; Upsher-Smith; Vertex Pharmaceuticals; Vifor Pharma; Vivus; VMware; Waters; Waters Corporation; Women's Choice Pharmaceuticals; Wyeth Nutrition/Nestle; Xanodyne Pharmaceuticals; Zydus

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.